C1orf66 inhibitors comprise a diverse array of chemical compounds that indirectly suppress the functional activity of C1orf66 by targeting various biochemical pathways. For instance, staurosporine, as a broad-spectrum kinase inhibitor, may curtail the activity of C1orf66 by preventing essential phosphorylation events, assuming its activity hinges on such modifications. Similarly, rapamycin's inhibition of mTOR signaling could reduce the cellular processes necessitating C1orf66, thereby decreasing its activity. Bortezomib, by inhibiting proteasome activity, might induce proteotoxic stress, which can have a downstream effect on the stability and function of C1orf66. Epigenetic modulation by trichostatin A could alter the expression landscape within the cell, potentially leading to a reduction in C1orf66 activity if it is subject to such epigenetic regulation.
Furthermore, inhibitors like LY 294002 and wortmannin target the PI3K/Akt pathway, which, if connected to C1orf66, could result in a reduced function of the protein. MEK inhibitors PD 98059 and U0126, as well as the p38 MAPK inhibitor SB 203580, might decrease C1orf66 activity by impeding signaling pathways it may rely on. Gefitinib, by blocking EGFR tyrosine kinase activity, also has the potential to diminish C1orf66 function if it is part of the EGFR pathway. The glycolysis inhibitor 2-Deoxy-D-glucose could indirectly lower C1orf66 activity by limiting metabolic resources required for its proper functioning. Lastly, nocodazole's disruption of microtubule dynamics may indirectly decrease C1orf66 activity by interfering with cell cycle-related processes. Collectively, this suite of inhibitors operates through distinct but interrelated mechanisms to decrease the functional activity of C1orf66, each interacting with specific cellular pathways that, when inhibited, contribute to the diminished activity of the protein. These inhibitors do not directly block C1orf66 but rather modulate the cellular environment and signaling webs that are crucial for its activity, resulting in a comprehensive indirect inhibition.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a potent non-selective inhibitor of protein kinases, which decreases the phosphorylation of multiple substrates, leading to reduced activity of target proteins, including C1orf66 if its function is phosphorylation-dependent. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin binds to FKBP12 and inhibits mTOR, which is involved in protein synthesis and cell growth. This inhibition can lead to a decrease in the cellular processes that require C1orf66, thereby diminishing its functional activity. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib is a proteasome inhibitor that prevents the degradation of ubiquitinated proteins, potentially increasing cellular stress and diminishing the functional activity of proteins like C1orf66 through proteotoxic stress. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Trichostatin A is a histone deacetylase inhibitor that can alter gene expression patterns, possibly leading to a reduction in the functional activity of C1orf66 through epigenetic modulation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY 294002 is a PI3K inhibitor that can suppress PI3K/Akt signaling, potentially diminishing the functional activity of C1orf66 if it is part of or regulated by this pathway. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD 98059 is a MEK inhibitor that impedes the MAPK/ERK pathway, which could lead to diminished signaling through pathways that involve C1orf66, thereby decreasing its functional activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB 203580 is a specific inhibitor of p38 MAPK, potentially decreasing the activity of proteins like C1orf66, if they are functionally connected to the p38 MAPK signaling pathway. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is another PI3K inhibitor, leading to the inhibition of the PI3K/Akt pathway, potentially diminishing the functional activity of C1orf66 if it is implicated in or regulated by this pathway. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an inhibitor of MEK1/2, which impedes the MAPK/ERK pathway, potentially diminishing the signaling pathways that involve C1orf66, thereby decreasing its functional activity. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Gefitinib is an EGFR tyrosine kinase inhibitor, which could diminish the functional activity of C1orf66 if it is downstream or affected by the EGFR signaling pathway. |